中国医学创新Issue(14)：57-59,3.DOI:10.3969/j.issn.1674-4985.2015.14.019
厄贝沙坦联合胺碘酮治疗非瓣膜性阵发性心房颤动的临床研究
Clinical Study on Irbesartan Combined Ammonia Amiodarone in Treatment of Non-valvular Paroxysmal Atrial Fibrillation
黄志新 1谢常林 1何正文1
作者信息
- 1. 广东省佛山市中医院禅城高新区医院 广东 佛山 528000
- 折叠
摘要
Abstract
Objective:To analyze the clinical efficacy of irbesartan combined with ammonia amiodarone in treatment of non-valvular paroxysmal atrial fibrillation.Method:76 patients with non-valvular paroxysmal atrial fibrillation admitted into our hospital from June 2011 to June 2013 were randomly divided into treatment group and control group,with 38 cases in each group on average.Patients in the treatment group were treated with irbesartan jointly with ammonia amiodarone,and the control group were treated with ammonia amiodarone.Result:The episodes and duration of atrial fibrillation of the patients in the treatment group after 9 months of treatment were significantly reduced,and the left atrial diameter of the control group was significantly higher than that of the treatment group,and the difference was statistically significant.Sinusrhythm maintenance rate(94.7%) was maintained after treatment, which was significantly better than that of the control group.All patients showed no adverse reactions due to drug administration.Conclusion:Treatment of non-valvular atrial fibrillation using irbesartan combined ammonia amiodarone can maintain sinus rhythm and suppress the enlargement left atrium,with significant efficacy.关键词
厄贝沙坦/胺碘酮/阵发性心房颤动Key words
Irbesartan/Ammonia amiodarone/Paroxysmal atrial fibrillation引用本文复制引用
黄志新,谢常林,何正文..厄贝沙坦联合胺碘酮治疗非瓣膜性阵发性心房颤动的临床研究[J].中国医学创新,2015,(14):57-59,3.
